期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
单孔胸腔镜肺癌根治术中迷走神经保护对手术效果及术后并发症的影响 被引量:10
1
作者 刘文健 姚龙 +1 位作者 王浩 张仁泉 《中国肿瘤外科杂志》 CAS 2022年第2期158-161,共4页
目的探讨在单孔胸腔镜行非小细胞肺癌(NSCLC)根治术中实施迷走神经保护对手术效果及术后并发症的影响。方法选取2021年1月至8月在安徽医科大学第一附属医院胸外科行单孔胸腔镜肺癌根治术治疗的84例NSCLC患者,其中54例在术中进行了迷走... 目的探讨在单孔胸腔镜行非小细胞肺癌(NSCLC)根治术中实施迷走神经保护对手术效果及术后并发症的影响。方法选取2021年1月至8月在安徽医科大学第一附属医院胸外科行单孔胸腔镜肺癌根治术治疗的84例NSCLC患者,其中54例在术中进行了迷走神经保护(研究组),30例未因多种原因无法行迷走神经保护(对照组)。比较两组手术时间、术中出血量、淋巴结清扫数、术后住院时间以及胃肠胀气、心律失常、肺部感染、排痰困难等术后并发症发生率。结果研究组与对照组手术时间[(92.17±26.16)min vs.(86.00±24.85)min,P=0.295]、术中出血量[(57.30±11.52)ml vs.(61.67±12.66)ml,P=0.111]、淋巴结清扫组数[(5.27±1.47)组vs.(5.53±1.47)组,P=0.448]差异无统计学意义。研究组术后住院时间短于对照组[(3.79±0.68)d vs.(5.36±0.96)d,P<0.001],研究组术后胃肠胀气发生率(12.96%vs.63.33%,P<0.001)、心律失常发生率(1.85%vs.26.67%,P<0.001)、肺部感染发生率(3.70%vs.20.00%,P=0.014)、排痰困难发生率(5.56%vs.23.33%,P=0.015)均低于对照组,差异有统计学意义。结论单孔胸腔镜下行NSCLC根治术中实施迷走神经保护是安全有效的,可保证手术的根治程度,同时降低术后并发症发生率。 展开更多
关键词 非小细胞肺癌 单孔胸腔镜根治术 迷走神经保护 并发症
下载PDF
单孔胸腔镜行早期肺癌切除术中迷走神经保护对术后恢复及并发症的影响
2
作者 朱建华 《浙江创伤外科》 2023年第11期2049-2051,共3页
目的本文旨在探索单孔胸腔镜行早期肺癌切除术中进行迷走神经保护对患者术后恢复及并发症的影响。方法回顾性分析本院2017年3月至2022年3月行单孔胸腔镜早期肺癌切除术患者154例,分为迷走神经未保护组与保护组。比较两组围手术期指标;... 目的本文旨在探索单孔胸腔镜行早期肺癌切除术中进行迷走神经保护对患者术后恢复及并发症的影响。方法回顾性分析本院2017年3月至2022年3月行单孔胸腔镜早期肺癌切除术患者154例,分为迷走神经未保护组与保护组。比较两组围手术期指标;比较两组迷走神经损伤并发症,腹胀、肺部感染、心律失常与咳嗽反射低下等。比较两组手术满意度。结果两组术中出血量、淋巴结清扫量差异均无统计学意义(P>0.05),未保护组的手术时间、肛门排气时间、住院时间均明显大于保护组(P<0.05)。未保护组术后迷走神经损伤并发症发生率为44.44%;保护组术后迷走神经损伤并发症发生率为19.78%,两组差异有统计学意义(P<0.05)。未保护组的手术满意度为68.25%,保护组的手术满意度为82.42%,未保护组的手术满意度明显高于保护组(P<0.05)。结论单孔胸腔镜引导下早期肺癌切除术行迷走神经保护疗效可靠,能明显降低患者术后因迷走神经损伤导致的脏器功能失调,促进早期功能恢复,提高手术满意度。 展开更多
关键词 早期肺癌 单孔胸腔镜 迷走神经保护 手术满意度
下载PDF
腹腔镜下迷走神经肝支保护降低远端胃癌根治术后胆囊结石发生率的临床疗效观察 被引量:14
3
作者 廖新华 车向明 +1 位作者 贾宗良 樊林 《腹腔镜外科杂志》 2018年第10期770-773,共4页
目的:评价在腹腔镜远端胃癌根治术中实施迷走神经肝支保护以降低术后胆囊结石发生率的作用。方法:选取81例胃癌患者进行前瞻性研究,随机分为迷走神经保护组(研究组)与非迷走神经保护组(对照组),行腹腔镜胃癌根治术加迷走神经保护或单纯... 目的:评价在腹腔镜远端胃癌根治术中实施迷走神经肝支保护以降低术后胆囊结石发生率的作用。方法:选取81例胃癌患者进行前瞻性研究,随机分为迷走神经保护组(研究组)与非迷走神经保护组(对照组),行腹腔镜胃癌根治术加迷走神经保护或单纯腹腔镜胃癌根治术。观察两组术中出血量、手术时间、术后淋巴结清扫数量、术后并发症等指标,并随访两年,了解是否发生胆囊结石。结果:两组术中出血量[(91.3±42.8) mL vs.(108.5±54.9) mL,P=0.151]、手术时间[(202.1±48.6) min vs.(184.5±54.1) min,P=0.175]、淋巴结清扫数量[(22.7±10.1) vs.(22.3±9.26),P=0.885]、术后并发症发生率(8.20%vs. 15%,P=0.379)差异无统计学意义。术后胆囊结石发生率研究组低于对照组(4.92%vs. 20%,P=0.038)。结论:腹腔镜下迷走神经肝支保护是安全的,可保证手术的根治程度,同时降低术后胆囊结石发生率。 展开更多
关键词 胃肿瘤 胃癌根治术 腹腔镜检查 迷走神经肝支保护 胆囊结石病
下载PDF
Cardiac Remote Conditioning and Clinical Relevance:All Together Now!
4
作者 Kristin Luther Yang Song +2 位作者 Yang Wang Xiaoping Ren W.Keith Jones 《Engineering》 SCIE EI 2015年第4期490-499,共10页
Acute myocardial infarction (AMI) is the leading cause of death and disability worldwide. Timely reperfusion is the standard of care and results in decreased infarct size, improving patient survival and prognosis. H... Acute myocardial infarction (AMI) is the leading cause of death and disability worldwide. Timely reperfusion is the standard of care and results in decreased infarct size, improving patient survival and prognosis. However, 25% of patients proceed to develop heart failure (HF) after myocardial infarction (MI) and 50% of these will die within five years. Since the size of the infarct is the major predictor of the outcome, including the development of HF, therapies to improve myocardial salvage have great potential. Over the past three decades, a number of stimuli have been discovered that activate endogenous cardioprotective pathways. In ischemic preconditioning (IPC) and ischemic postconditioning, ischemia within the heart initiates the protection. Brief reversible episodes of ischemia in vascular beds remote from the heart can also trigger cardioprotection when applied before, during, or immediately after myocardial ischemia-- known as remote ischemic pre-, per-, and post-conditioning, respectively. Although the mechanism of remote ischemic preconditioning (RIPC) has not yet been fully elucidated, many mechanistic components are shared with IPC. The discovery of RIPC led to research into the use of remote non-ischemic stimuli including nerve stimulation (spinal and vagal), and electroacupuncture (EA). We discovered and, with others, have elucidated mechanistic aspects of a non- ischemic phenomenon we termed remote preconditioning of trauma (RPCT). RPCT operates via neural stimulation of skin sensory nerves and has similarities and differences to nerve stimulation and EA conducted at acupoints. We show herein that RPCT can be mimicked using electrical stimulation of the abdominal midline (EA-like treatment) and that this modality of activating cardioprotection is powerful as both a preconditioning and a postconditioning stimulus (when applied at reperfusion). Investigations of these cardioprotective phenomena have led to a more integrative understanding of mechanisms related to cardioprotection, and in the last five to ten years, it has become clear that the mechanisms are similar, whether induced by ischemic or non-ischemic stimuli. Taking together much of the data in the literature, we propose that all of these cardioprotective "conditioning" phenomena represent activation from different entry points of a cardiac conditioning network that converges upon specific mediators and effectors of myocardial cell survival, including NF-KB, Stat3/5, protein kinase C, bradykinin, and the mitoKA^P channel. Nervous system pathways may represent a novel mechanism for initiating conditioning of the heart and other organs. IPC and RIPC have proven difficult to translate clinically, as they have associated risks and cannot be used in some patients. Because of this, the use of neural and nociceptive stimuli is emerging as a potential non-ischemic and non-traumatic means to initiate cardiac conditioning. Clinical relevance is underscored by the demonstration of postconditioning with one of these modalities, supporting the conclusion that the development of pharmaceuticals and electroceuticals for this purpose is an area ripe for clinical development. 展开更多
关键词 remote cardioprotection cardiac conditioning non-ischemic conditioning peripheral nociceptive stimulus neural and molecular mechanism clinical feasibility electroceuticals
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部